Prolonged Exposure Therapy
BehavioralExposure therapy for PTSD
NCT Number: NCT06296186
The goal of this clinical trial is to learn if receiving Prolonged Exposure Therapy for PTSD in massed format (multiple sessions weekly) is as effective as receiving it with sessions once per week among veterans with PTSD and substance use disorder in intensive outpatient substance use treatment. The main questions it aims to answer are:
* Will the massed format help participants complete and benefit from Prolonged Exposure in terms of PTSD symptoms? * Will it help participants reduce substance use? Participants who are in intensive substance use treatment will be asked to complete Prolonged Exposure with either weekly sessions or multiple sessions per week.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
VA San Diego Healthcare System, San Diego, California, United States
Posttraumatic stress disorder (PTSD) and substance use disorder (SUD) often co-occur. PTSD+SUD comorbidity is associated with more severe PTSD, worse treatment outcomes for substance use, greater suicide risk and worse functioning than having one of these disorders. First-line treatments for PTSD, particularly Prolonged Exposure Therapy (PE), are effective in treating PTSD among those with a SUD, and delivering these treatments concurrent to SUD programming is recommended by the VA/DoD Clinical Practice Guidelines. While PE is one of the most effective treatment options for PTSD among those with PTSD+SUD, effects are smaller and dropout is higher than among people with PTSD without a SUD. A promising way to enhance outcomes is to offer PE in a massed format (M-PE; i.e., multiple sessions per week instead of once weekly). M-PE has been shown to be effective in improving PTSD symptoms and substantially reducing dropout in military and Veteran populations. Preliminary findings suggest M-PE delivered concurrent to intensive SUD programming is a promising strategy that warrants further study. Evaluating the effectiveness of M- PE delivery in of SUD intensive outpatient programming (IOP) in improving PTSD and other mental health outcomes and reducing dropout as compared to weekly PE delivery (W-PE) is the necessary next step in this critical research.
The primary goal of this project is to determine if a promising way to treat PTSD among those with SUD, M-PE, will help Veterans with their PTSD symptoms and lead to better treatment completion rates more than PE delivered weekly and if the massed format will reduce substance use comparably to weekly PE among those in intensive SUD treatment. The study will also evaluate if M-PE helps Veterans function better and feel less depressed. M-PE is a one-on-one talk therapy that is delivered over twelve sessions several times a week. The therapy is brief because of the massed format so that it can be delivered at times when lengthy interventions may not be realistic, such as military mental health clinics on bases where military personnel may be getting ready to redeploy. The research team's preliminary work with Veterans in intensive SUD treatment showed M-PE to lead to improvements in PTSD and depression symptoms with no dropout, making this larger evaluation of M-PE compared to PE delivered in the traditional longer (weekly) format a critical next step. The study will accomplish this by randomly assigning participants who are in intensive SUD treatment to receive either M-PE or W-PE. The study will have 200 Veterans who served post 9/11 go through this study and the entire study is expected to take four years to complete. The study will run the study across four VAs (San Diego, Tampa, Chicago, and Atlanta).
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Exposure therapy for PTSD
Time frame: At 4-, 16-, 28-, and 40-weeks post-first therapy session
Measures PTSD symptom severity, score range 0-80, higher scores mean greater symptom severity
Time frame: At 4-, 16-, 28-, and 40-weeks post-first therapy session
Measures percent days of alcohol or other drug use, score range 0-100%, higher scores indicate greater percent days of use
Time frame: 16 weeks
Percent of participants completing all sessions of psychotherapy, range is 0-100%, higher number means greater percent completed therapy
Time frame: At 4-, 16-, 28-, and 40-weeks post-first therapy session
Depression symptom severity, range = 0-27, higher scores mean greater depression symptom severity
Time frame: At 4-, 16-, 28-, and 40-weeks post-first therapy session
Measures severity of impairment in psychosocial functioning, scores = 0-100, higher scores indicate greater impairment
Time frame: 16 weeks
Measures satisfaction with treatment, scores range from 8 to 32. higher scores indicate greater satisfaction with treatment
Contact information is provided by the study sponsor or research team.
Kaitlyn Panza, PhD
CONTACT
Sonya Norman, PhD
CONTACT
Veterans Medical Research Foundation
Other
Clinical Effectiveness and Implementation of Massed Prolonged Exposure for PTSD Among Veterans in Intensive Outpatient Substance Use Treatment (MPE)
Acronym: PREVAIL
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04581434
Chemically-Induced Disorders, Mental Disorders
San Diego, California, United States
View Trial DetailsNCT02742532
Alcohol Use Disorder, Alcohol-Related Disorders
San Diego, California, United States
View Trial DetailsNCT02611843
Chemically-Induced Disorders, Mental Disorders
Syracuse, New York, United States
View Trial DetailsNCT07665502
Chemically-Induced Disorders, Combat Disorders
New York, United States
View Trial Details